Shanghai Registry of Acute Coronary Events

Terminated

• Conditions: Coronary Artery Disease; Acute Coronary Syndrome
• Interventions: Device: drug-eluting stent; Drug: Tirofiban

• Registration Number: NCT00713557
• Lead Sponsor: Shanghai Jiao Tong University School of Medicine

Brief Summary

SRACE is an multicenter observational database of outcomes for patients who are hospitalized with an acute coronary events. SRACE includes over 20 hospitals in Shanghai China that have enrolled a total of more than 3,000 patients since 2005, with an annual enrollment of 500 patients. The major purpose of the SRACE program is to evaluate the prognosis of patients admitted to the hospital due to acute coronary events, comparing different therapeutic strategies, in-hospital transferring system, and so on. All participating physicians receive confidential quarterly reports showing ther outcomes side-by-side with the aggregate outcomes of all participating hospitals.

Detailed Description

consecutive patients with STEMI who presented symptoms within 12 hours and treated by primary PCI in Shanghai, were enrolled in the prospective sysytem. Several strategies were applied in these patients, including physician vs. patient transfer strategy, upsteam vs. downstream strategy, Firebird stent vs. Excel stent (bio-absorbable SES), etc. Once the patient was randomized to one of these study, he will be denied to the others. Clinical and angiographic outcomes were compared, with the final purpose to find an optimal strategy in treating AMI patients.

Study Timeline

• Study Start: 2005-03
• Study First Submitted: 2008-07-07
• Study First Submitted QC: 2008-07-10
• Study First Posted: 2008-07-11
• Status Verified: 2016-10
• Last Update Submitted: 2016-10-12
• Last Update Posted: 2016-10-13
• Primary Completion: 2018-01

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 20000

Inclusion Criteria

• patients admitted to the hospital with acute coronary syndrome and received medical or interventional treatment

Exclusion Criteria

• non ACS patients;
• complicated with other lethal disease
• predicted life span less than 12 months
• known allergy history to any anti-platelet or anti-thrombin medicine
• unconscious at the time of arrival at the hospital

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
1	drug-eluting stent	patients with acute ST-elevation myocardial infarction and receiving primary percutaneous coronary intervention Subgroup: Patient Transferring vs. Physician Transferring strategy
2	drug-eluting stent	patients with acute ST-elevation myocardial infarction treated by thrombolysis or facilitated PCI Subgroup: upstream use of Tirofiban + primary PCI vs. downstream use of tirofiban + primary PCI
2	Tirofiban	patients with acute ST-elevation myocardial infarction treated by thrombolysis or facilitated PCI Subgroup: upstream use of Tirofiban + primary PCI vs. downstream use of tirofiban + primary PCI
3	drug-eluting stent	patients with non-ST-elevation ACS treated by immediate PCI
4	drug-eluting stent	patients with non ST-elevation ACS treated by elective PCI

Primary Outcome Measures

Name	Time	Method
major adverse cardiac events(MACE), including death, non-fatal re-MI, and target vessel revascularization	in-hospital, 30d, and long-term follow-up

Secondary Outcome Measures

Name	Time	Method
stroke, stent thrombosis	in-hospital, 30d, and long-term follow-up

Trial Locations

Locations (1)

Dept. of Cardiology, Ruijin Hospital; 🇨🇳 Shanghai, Shanghai, China